Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1161-1180 of 1,738 trials

Extensive-Stage Small-Cell Lung Cancer: THOR Trial

We are studying a combination of chemotherapy, pembrolizumab, and olaparib for patients with extensive-stage small-cell lung cancer. The goal is to see if this approach improves survival and response rates compared to standard treatments.

Extensive-Stage Small-Cell Lung Cancer6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPulmonology

Advanced Respiratory Diseases: Inhaled Furosemide and Levodropropizine

We are studying whether inhaled furosemide can help reduce shortness of breath in patients with advanced respiratory diseases. We also want to see if adding oral levodropropizine enhances this effect.

Difficulty Breathing (Dyspnea)Efficacy phase (II)No PlaceboStandard MedicinesInternal MedicinePulmonology

Alzheimer's Dementia: ITI-1284 for Agitation

We are studying whether ITI-1284 can help reduce agitation in patients with Alzheimer's dementia compared to a placebo. The trial will also assess the safety and tolerability of this new treatment.

Alzheimer's Disease3-6 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPsychiatry

Rett Syndrome: Leriglitazone Study for Children

We are testing the safety and effects of a new medication, leriglitazone, in children with Rett Syndrome. The study aims to understand its impact on development and caregiver challenges.

Rett Syndrome1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurologyPediatrics

Irritable Bowel Syndrome: GSL-01-001 Treatment

We are testing a new oral medication for people with Irritable Bowel Syndrome to see if it helps control symptoms like pain and bloating. The study also aims to evaluate its safety and impact on quality of life.

Irritable Bowel Syndrome (IBS)6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesGastroenterology

Chronic Lymphocytic Leukemia: Venetoclax with Ibrutinib and Rituximab

We are studying a combination of venetoclax, rituximab, and ibrutinib for treatment-naïve patients with chronic lymphocytic leukemia. The aim is to see if this approach can lead to undetectable minimal residual disease.

Chronic Lymphocytic Leukaemia>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Leukemia: Venetoclax with Stem Cell Transplant

We are evaluating the safety and effectiveness of Venetoclax combined with standard treatment for patients with high-risk MDS, CMML, or sAML undergoing stem cell transplantation. This study aims to improve outcomes and reduce complications during treatment.

Leukemia>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHematologyOncology

Painful Diabetic Peripheral Neuropathy: VX-993 Study

We are evaluating a new oral medication, VX-993, for people with pain from diabetic peripheral neuropathy. The study aims to determine if it effectively reduces pain and is safe to use.

Diabetic Peripheral Neuropathic Pain3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementDiabetologyNeurology

NPM1-Mutated Acute Myeloid Leukemia: Eltanexor Study

We are evaluating a new drug called eltanexor for patients with relapsed or refractory NPM1-mutated acute myeloid leukemia. The study aims to see if it is safe and effective in treating this condition.

Acute Myeloid LeukemiaEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Lupus Nephritis: MSV-ALLO® Treatment Study

We are testing a new cell therapy for lupus nephritis to see if it helps patients achieve remission. The study compares this treatment to a placebo to evaluate its safety and effectiveness.

Lupus Nephritis3-6 monthsEfficacy phase (II)Confirmation phase (III)11-15 visitsInvestigational MedicinesNephrologyRheumatology

Psoriasis: [18F]Fluoride PET-CT Imaging Study

We are investigating if [18F]Fluoride PET-CT scans can detect early bone changes in psoriasis patients at risk for psoriatic arthritis. This study aims to see if this imaging method is effective for early detection.

Psoriasis>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementDermatologyRheumatology

Colorectal Cancer Prevention: Mesalamine for Lynch Syndrome

We are studying whether mesalamine can help prevent colorectal cancer in patients with Lynch syndrome. This trial compares mesalamine to a placebo to see if it reduces the occurrence of tumors.

Lynch Syndrome>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesPartially RemoteGastroenterologyOncology

Osteosarcoma: Mifamurtide with Chemotherapy

We are studying whether adding mifamurtide to standard chemotherapy helps improve outcomes for patients with high-risk osteosarcoma. This trial is for individuals aged 2 to 50 who are newly diagnosed with this aggressive cancer.

High-Risk Osteosarcoma6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Gastroenteropancreatic Neuroendocrine Tumors: New Liver Treatment

We are studying a new way to deliver radiolabeled treatments directly to the liver for patients with GEP-NET and dominant liver metastases. This trial aims to see if this method improves treatment effectiveness and safety.

Gastroenteropancreatic Neuroendocrine Tumors>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyInternal MedicineOncology

Relapsed or Refractory Tumors: AcSé-ESMART Trial

We are studying new treatment options for children and adolescents with hard-to-treat tumors. The goal is to see if these treatments are safe and effective based on the specific characteristics of their tumors.

Pediatric Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncologyPediatrics

Kidney Transplant: Optimal Dose of Grafalon®

We are studying the best dose of Grafalon® for kidney transplant patients with low immunological risk. This trial aims to prevent complications and evaluate the medication's safety and effects on kidney function and infections.

Kidney TransplantKidney Insufficiency>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineNephrology

Thyroid Eye Disease: TOUR006 Treatment Study

We are investigating whether the new treatment TOUR006 can reduce eye bulging in adults with thyroid eye disease. Participants will receive either the treatment or a placebo to compare effects.

Thyroid Eye Disease1-2 yearsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementEndocrinologyOphthalmology

Lung Cancer: Pembrolizumab and Lenvatinib Combination Therapy

We are studying a new combination treatment for patients with operable Non-Small-Cell Lung Cancer to see if it improves response rates before surgery. We also aim to identify markers that may predict how well patients respond to this therapy.

Non-Small-Cell Lung Cancer1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncologyPulmonology

Chronic Lymphocytic Leukemia: Ibrutinib and Obinutuzumab Treatment

We are studying a combination of ibrutinib and obinutuzumab for newly diagnosed patients with Chronic Lymphocytic Leukemia. The aim is to see if this treatment effectively reduces cancer cells in the bone marrow.

Chronic Lymphocytic Leukemia (CLL)>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Advanced Solid Tumors: OSE-279 Treatment Study

We are investigating a new monoclonal antibody, OSE-279, for patients with advanced solid tumors or lymphomas. The study aims to find the best dose and evaluate its safety and effectiveness compared to existing treatments.

Stage IV Non-Small Cell Lung CancerAdvanced Solid TumorsLymphoma1-2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology